{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:36:21Z","timestamp":1792290981511,"version":"4.4.0"},"reference-count":82,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["107-2320-B-182-044, 109-2320-B-010-024"],"award-info":[{"award-number":["107-2320-B-182-044, 109-2320-B-010-024"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPG3K1441C, MRPG3K1441"],"award-info":[{"award-number":["CMRPG3K1441C, MRPG3K1441"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Glioblastoma (GBM), the most lethal type of brain tumor in adults, has considerable cellular heterogeneity. The standard adjuvant chemotherapeutic agent for GBM, temozolomide (TMZ), has a modest response rate due to the development of drug resistance. Multiple studies have shown that valproic acid (VPA) can enhance GBM tumor control and prolong survival when given in conjunction with TMZ. However, the beneficial effect is variable. In this study, we analyzed the impact of VPA on GBM patient survival and its possible correlation with TMZ treatment and\n                    <jats:italic>p53<\/jats:italic>\n                    gene mutation. In addition, the molecular mechanisms of TMZ in combination with VPA were examined using both p53 wild-type and p53 mutant human GBM cell lines. Our analysis of clinical data indicates that the survival benefit of a combined TMZ and VPA treatment in GBM patients is dependent on their\n                    <jats:italic>p53<\/jats:italic>\n                    gene status. In cellular experiments, our results show that VPA enhanced the antineoplastic effect of TMZ by enhancing p53 activation and promoting the expression of its downstream pro-apoptotic protein, PUMA. Our study indicates that GBM patients with wild-type\n                    <jats:italic>p53<\/jats:italic>\n                    may benefit from a combined TMZ+VPA treatment.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2021.722754","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T13:19:00Z","timestamp":1633094340000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Valproic Acid Enhanced Temozolomide-Induced Anticancer Activity in Human Glioma Through the p53\u2013PUMA Apoptosis Pathway"],"prefix":"10.3389","volume":"11","author":[{"given":"Hong-Chieh","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Chen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiung-Yin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Jui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Wei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Rou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Tsui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO Classification of Tumours of the Central Nervous System","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/now207","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013","volume":"18","author":"Ostrom","year":"2016","journal-title":"Neuro Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov249","article-title":"Years of Potential Life Lost for Brain and CNS Tumors Relative to Other Cancers in Adults in the United States, 2010","volume":"18","author":"Rouse","year":"2016","journal-title":"Neuro Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/srep07979","article-title":"The Evidence of Glioblastoma Heterogeneity","volume":"5","author":"Soeda","year":"2015","journal-title":"Sci Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1219747110","article-title":"Intratumor Heterogeneity in Human Glioblastoma Reflects Cancer Evolutionary Dynamics","volume":"110","author":"Sottoriva","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"B7","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1038\/cddis.2013.388","article-title":"O6-Methylguanine DNA Methyltransferase as a Promising Target for the Treatment of Temozolomide-Resistant Gliomas","volume":"4","author":"Fan","year":"2013","journal-title":"Cell Death Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI59334","article-title":"Alkylpurine-DNA-N-Glycosylase Confers Resistance to Temozolomide in Xenograft Models of Glioblastoma Multiforme and is Associated With Poor Survival in Patients","volume":"122","author":"Agnihotri","year":"2012","journal-title":"J Clin Invest"},{"key":"B10","article-title":"Multifaceted Resistance of Gliomas to Temozolomide","volume":"8","author":"Bocangel","year":"2002","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-010-0707-1","article-title":"Enhancement of Temozolomide-Induced Apoptosis by Valproic Acid in Human Glioma Cell Lines Through Redox Regulation","volume":"89","author":"Chen","year":"2011","journal-title":"J Mol Med (Berl)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.506","article-title":"Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM\/CHK2 Pathway in Glioma","volume":"53","author":"Lin","year":"2021","journal-title":"Cancer Res Treat"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2773","article-title":"Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair","volume":"77","author":"Lu","year":"2017","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","article-title":"Temozolomide Resistance in Glioblastoma Multiforme","volume":"3","author":"Lee","year":"2016","journal-title":"Genes Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2019.4788","article-title":"Targeted Therapy Based on P53 Reactivation Reduces Both Glioblastoma Cell Growth and Resistance to Temozolomide","volume":"54","author":"Forte","year":"2019","journal-title":"Int J Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The Somatic Genomic Landscape of Glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1470-2045(10)70053-X","article-title":"Isocitrate Dehydrogenase-1 Mutations: A Fundamentally New Understanding of Diffuse Glioma? [Review]","volume":"12","author":"Kloosterhof","year":"2011","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.celrep.2019.07.001","article-title":"Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas","volume":"28","author":"Donehower","year":"2019","journal-title":"Cell Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/nrneurol.2009.197","article-title":"MGMT Promoter Methylation in Malignant Gliomas: Ready for Personalized Medicine","author":"Weller","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8013575","article-title":"Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives","volume":"2017","author":"Szopa","year":"2017","journal-title":"BioMed Res Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407279","article-title":"Glioma Groups Based on 1p\/19q, IDH, and TERT Promoter Mutations in Tumors","volume":"372","author":"Eckel-Passow","year":"2015","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216100-00003","article-title":"Basic Pharmacology of Valproate: A Review After 35 Years of Clinical Use for the Treatment of Epilepsy","volume":"16","author":"Loscher","year":"2002","journal-title":"CNS Drugs"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2016.17.2.463","article-title":"Roles of Valproic Acid in Improving Radiation Therapy for Glioblastoma: A Review of Literature Focusing on Clinical Evidence","volume":"17","author":"Ochiai","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2014.06.015","article-title":"Survival Analysis for Valproic Acid Use in Adult Glioblastoma Multiforme: A Meta-Analysis of Individual Patient Data and a Systematic Review","volume":"23","author":"Yuan","year":"2014","journal-title":"Seizure"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not057","article-title":"Effect of Valproic Acid on Seizure Control and on Survival in Patients With Glioblastoma Multiforme","volume":"15","author":"Kerkhof","year":"2013","journal-title":"Neuro Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2167-1","article-title":"Valproic Acid Reduces Hair Loss and Improves Survival in Patients Receiving Temozolomide-Based Radiation Therapy for High-Grade Glioma","volume":"73","author":"Watanabe","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14716","article-title":"Valproic Acid Inhibits Glioblastoma Multiforme Cell Growth via Paraoxonase 2 Expression","volume":"8","author":"Tseng","year":"2017","journal-title":"Oncotarget"},{"key":"B28","doi-asserted-by":"publisher","first-page":"eng","DOI":"10.3390\/medsci7030051","article-title":"HDAC2 Inhibitor Valproic Acid Increases Radiation Sensitivity of Drug-Resistant Melanoma Cells","volume":"7","author":"Kalal","year":"2019","journal-title":"Med Sci (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-014-1713-x","article-title":"The Effect of Valproic Acid in Combination With Irradiation and Temozolomide on Primary Human Glioblastoma Cells","volume":"122","author":"Hosein","year":"2015","journal-title":"J Neurooncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/987495","article-title":"Valproic Acid Downregulates the Expression of MGMT and Sensitizes Temozolomide-Resistant Glioma Cells","volume":"2012","author":"Ryu","year":"2012","journal-title":"J BioMed Biotechnol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-018-3817-7","article-title":"Valproic Acid Treatment Response In Vitro is Determined by TP53 Status in Medulloblastoma","volume":"34","author":"Mascaro-Cordeiro","year":"2018","journal-title":"Childs Nerv Syst"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.315","article-title":"Synergistic Induction of P53 Mediated Apoptosis by Valproic Acid and Nutlin-3 in Acute Myeloid Leukemia","volume":"26","author":"McCormack","year":"2012","journal-title":"Leukemia"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2009.0629","article-title":"HDAC Inhibitor, Valproic Acid, Induces P53-Dependent Radiosensitization of Colon Cancer Cells","volume":"24","author":"Chen","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6991","article-title":"Hydroxyurea Synergizes With Valproic Acid in Wild-Type P53 Acute Myeloid Leukaemia","volume":"7","author":"Leitch","year":"2016","journal-title":"Oncotarget"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.315","article-title":"Mutations in Isocitrate Dehydrogenase 1 and 2 Occur Frequently in Intrahepatic Cholangiocarcinomas and Share Hypermethylation Targets With Glioblastomas","volume":"25","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3109\/02688697.2011.638996","article-title":"Effect of Valproic Acid on the Outcome of Glioblastoma Multiforme","volume":"26","author":"Tsai","year":"2012","journal-title":"Br J Neurosurg"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/humu.23035","article-title":"TP53 Variations in Human Cancers: New Lessons From the IARC TP53 Database and Genomics Data","volume":"37","author":"Bouaoun","year":"2016","journal-title":"Hum Mutat"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2718","article-title":"P53 and E2f: Partners in Life and Death","volume":"9","author":"Polager","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdg315","article-title":"The Histone Deacetylase Inhibitor Valproic Acid Selectively Induces Proteasomal Degradation of HDAC2 [Research Support, Non-U.S. Gov\u2019t]","volume":"22","author":"Kramer","year":"2003","journal-title":"EMBO J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3188-2","article-title":"Silencing of Histone Deacetylase 2 Suppresses Malignancy for Proliferation, Migration, and Invasion of Glioblastoma Cells and Enhances Temozolomide Sensitivity","volume":"78","author":"Zhang","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nature07385","article-title":"Comprehensive Genomic Characterization Defines Human Glioblastoma Genes and Core Pathways","volume":"455","year":"2008","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Summary [Review]","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"86","DOI":"10.4103\/jnrp.jnrp_417_17","article-title":"Recurrent Glioblastomas Exhibit Higher Expression of Biomarkers With Stem-Like Properties","volume":"9","author":"Nandeesh","year":"2018","journal-title":"J Neurosci Rural Pract"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23219","article-title":"MGMT in Primary and Recurrent Human Glioblastomas After Radiation and Chemotherapy and Comparison With P53 Status and Clinical Outcome [Comparative Study Research Support, Non-U.S. Gov\u2019t]","volume":"122","author":"Wiewrodt","year":"2008","journal-title":"Int J Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.74.6.779","article-title":"P53, Mdm2, EGFR, and Msh2 Expression in Paired Initial and Recurrent Glioblastoma Multiforme","volume":"74","author":"Stark","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.28.1.119","article-title":"Induction of P53-Mediated Apoptosis and Recovery of Chemosensitivity Through P53 Transduction in Human Glioblastoma Cells by Cisplatin","volume":"28","author":"Park","year":"2006","journal-title":"Int J Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2014.08.013","article-title":"Actin Cytoskeleton Organization, Cell Surface Modification and Invasion Rate of 5 Glioblastoma Cell Lines Differing in PTEN and P53 Status","volume":"330","author":"Djuzenova","year":"2015","journal-title":"Exp Cell Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-013-0871-3","article-title":"Current Understanding of the Role and Targeting of Tumor Suppressor P53 in Glioblastoma Multiforme [Review]","volume":"34","author":"England","year":"2013","journal-title":"Tumour Biol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3711","article-title":"Unravelling Mechanisms of P53-Mediated Tumour Suppression","volume":"14","author":"Bieging","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-Year Analysis of the EORTC-NCIC Trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12885-021-07800-0","article-title":"Clinical Features Associated With the Efficacy of Chemotherapy in Patients With Glioblastoma (GBM): A Surveillance, Epidemiology, and End Results (SEER) Analysis","volume":"21","author":"Wen","year":"2021","journal-title":"BMC Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1215\/S1152851703000620","article-title":"Prognostic Factors for Survival of Patients With Glioblastoma: Recursive Partitioning Analysis","volume":"6","author":"Lamborn","year":"2004","journal-title":"Neuro Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov238","article-title":"Prognostic Relevance of Epilepsy at Presentation in Glioblastoma Patients","volume":"18","author":"Berendsen","year":"2016","journal-title":"Neuro Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-013-0345-4","article-title":"IDH1 and IDH2 Mutations in Gliomas","volume":"13","author":"Cohen","year":"2013","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-013-0934-5","article-title":"IDH1 Mutation is Associated With Improved Overall Survival in Patients With Glioblastoma: A Meta-Analysis","volume":"34","author":"Cheng","year":"2013","journal-title":"Tumour Biol: J Int Soc Oncodevel Biol Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-017-2584-8","article-title":"Prophylactic Anticonvulsants in Patients With Primary Glioblastoma","volume":"135","author":"Wali","year":"2017","journal-title":"J Neurooncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3171\/2012.12.JNS111970","article-title":"A Prospective Randomized Trial of Perioperative Seizure Prophylaxis in Patients With Intraparenchymal Brain Tumors","volume":"118","author":"Wu","year":"2013","journal-title":"J Neurosurg"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e21147","DOI":"10.1097\/MD.0000000000021147","article-title":"Effect of Valproic Acid on Overall Survival in Patients With High-Grade Gliomas Undergoing Temozolomide: A Nationwide Population-Based Cohort Study in Taiwan","volume":"99","author":"Kuo","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2018.09.019","article-title":"The Survival Effect of Valproic Acid in Glioblastoma and its Current Trend: A Systematic Review and Meta-Analysis","volume":"174","author":"Lu","year":"2018","journal-title":"Clin Neurol Neurosurg"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00127","article-title":"The Clinical Significance of O(6)-Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-Analysis","volume":"9","author":"Zhao","year":"2018","journal-title":"Front Neurol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-010-0153-6","article-title":"MGMT Promoter Methylation in Malignant Gliomas","volume":"5","author":"Riemenschneider","year":"2010","journal-title":"Target Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2017.10.007","article-title":"Comparative Assessment of Three Methods to Analyze MGMT Methylation Status in a Series of 350 Gliomas and Gangliogliomas","volume":"213","author":"Wang","year":"2017","journal-title":"Pathol Res Pract"},{"key":"B64","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/PAI.0b013e31802fac2f","article-title":"MGMT Immunohistochemical Expression and Promoter Methylation in Human Glioblastoma","volume":"16","author":"Rodriguez","year":"2008","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab105","article-title":"MGMT Promoter Methylation Testing to Predict Overall Survival in People With Glioblastoma Treated With Temozolomide: A Comprehensive Meta-Analysis Based on a Cochrane Review","volume":"23","author":"Brandner","year":"2021","journal-title":"Neuro Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209785","article-title":"Apoptosis in Malignant Glioma Cells Triggered by the Temozolomide-Induced DNA Lesion O6-Methylguanine","volume":"26","author":"Roos","year":"2007","journal-title":"Oncogene"},{"key":"B67","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3390\/cancers10090297","article-title":"The P53 Pathway in Glioblastoma","volume":"10","author":"Zhang","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/s1097-2765(01)00214-3","article-title":"PUMA, a Novel Proapoptotic Gene, is Induced by P53","volume":"7","author":"Nakano","year":"2001","journal-title":"Mol Cell"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.45","article-title":"PUMA, a Potent Killer With or Without P53 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov\u2019t Review]","author":"Yu","year":"2008","journal-title":"Oncogene"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2005.16.685","article-title":"Therapeutic Efficacy of PUMA for Malignant Glioma Cells Regardless of P53 Status [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov\u2019t Research Support, U.S. Gov\u2019t, P.H.S.]","volume":"16","author":"Ito","year":"2005","journal-title":"Hum Gene Ther"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2015.3255","article-title":"P53 Upregulated Modulator of Apoptosis Sensitizes Drug-Resistant U251 Glioblastoma Stem Cells to Temozolomide Through Enhanced Apoptosis [Research Support, Non-U.S. Gov\u2019t]","volume":"11","author":"Miao","year":"2015","journal-title":"Mol Med Rep"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.3390\/ijms20071562","article-title":"Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide","author":"He","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0807","article-title":"Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients","volume":"10","author":"Ostermann","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1349","article-title":"The Neuropharmacokinetics of Temozolomide in Patients With Resectable Brain Tumors: Potential Implications for the Current Approach to Chemoradiation","volume":"15","author":"Portnow","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B75","article-title":"Analysis of the P53 Gene and its Expression in Human Glioblastoma Cells","volume":"54","author":"Van Meir","year":"1994","journal-title":"Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s002620050355","article-title":"Immunochemotherapy of Malignant Glioma: Synergistic Activity of CD95 Ligand and Chemotherapeutics","volume":"44","author":"Roth","year":"1997","journal-title":"Cancer Immunol Immunother"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphs.2018.06.014","article-title":"Valproic Acid Attenuates Immunosuppressive Function of Myeloid-Derived Suppressor Cells","volume":"137","author":"Xie","year":"2018","journal-title":"J Pharmacol Sci"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-3498","article-title":"Intrinsic Anticancer Drug Resistance of Malignant Melanoma Cells is Abrogated by IFN-Beta and Valproic Acid","volume":"71","author":"Roos","year":"2011","journal-title":"Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.21149","article-title":"Valproic Acid Induces the Hyperacetylation of P53, Expression of P53 Target Genes, and Markers of the Intrinsic Apoptotic Pathway in Midorganogenesis Murine Limbs","volume":"104","author":"Paradis","year":"2015","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.12.3","article-title":"Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need to Succeed [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov\u2019t Review]","volume":"4","author":"Gryder","year":"2012","journal-title":"Future Med Chem"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S69140","article-title":"Panobinostat for the Treatment of Multiple Myeloma: The Evidence to Date [Review]","volume":"6","author":"Bailey","year":"2015","journal-title":"J Blood Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216634178","article-title":"Belinostat for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma [Review]","volume":"23","author":"Campbell","year":"2017","journal-title":"J Oncol Pharm Practice: Off Publ Int Soc Oncol Pharm Practitioners"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.722754\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T13:19:05Z","timestamp":1633094345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.722754\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":82,"alternative-id":["10.3389\/fonc.2021.722754"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.722754","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,1]]},"article-number":"722754"}}